Compare KLA Corp. (KLAC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Recursion Pharmaceuticals Inc — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: KLA Corp. is far larger — about 120× Recursion Pharmaceuticals Inc's market cap, and KLA Corp. pays a 0.47% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KLAC | RXRX | |
|---|---|---|
Market Cap | $256.72B | $2.14B |
Volume | 9,970,753 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $301.71 | $6.79 |
52-Week Low | $98.28 | $2.84 |
Typical Hold Time | 60 Days | 23 Days |
Enterprise Value | $257.97B | $1.66B |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $195.57, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $193. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, revenue growth accelerating to $12.16B in 2025, and exceptional profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57B backlog and competitive positioning against AMAT and ASML.
KLA presents a compelling growth opportunity with analyst consensus price target of $223.88 (14.5% upside) and strong institutional support, though elevated valuation ratios (P/E 53.75, P/S 19.12) and semiconductor cycle sensitivity warrant caution. The stock's outlook remains positive driven by AI infrastructure spending and advanced packaging growth, with key risks including competition intensity and potential margin pressure from increased investments.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
